Investigational Drugs

Investigational drugs for NAFLD are derived from global clinical trials with the latest progress, and detailed drug properties are extracted from DrugBank and PubChem. For each drug, related therapeutic strategies, targets, and clinical trials in NAFLDkb are presented with knowledge graphs.

stats1
stats2

Search for:

     Obesity
13 records.
Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D088 CP-945598 Chemical drug DB11745 CNR1; CB-1 antagonist -- Under clinical trials Details
D119 Elafibranor Chemical drug DB05187 PPARA; PPARD; PPARG Anti-inflammatory Failed in clinical trials Details
D160 Growth Hormone Biological drug DB00052 GHR ligand; PRLR ligand -- Under clinical trials Details
D204 Licogliflozin Chemical drug DB15048 SGLT1 inhibitor; SGLT2 inhibitor Improve insulin resistance Under clinical trials Details
D217 Mastiha Biological extract -- -- -- Under clinical trials Details
D260 Orlistat Chemical drug DB01083 FASN inhibitor Enhance lipid metabolism Under clinical trials Details
D271 Phentermine Chemical drug DB00191 MAOB antagonist; MAOA antagonist; SLC6A2 inhibitor; SLC6A3 inhibitor; SLC6A4 inhibitor; SLC6A2 stimulator; SLC6A3 stimulator Anorexic; CNS stimulant Under clinical trials Details
D305 Rimonabant Chemical drug DB06155 CNR1 antagonist Antialcoholic drug; CNS drug Under clinical trials Details
D327 Semaglutide Chemical drug DB13928 GLP1R agonist Antidiabetic drug Under clinical trials Details
D333 Sibutramine Chemical drug DB01105 -- -- Under clinical trials Details
D343 Somatropin Biological drug DB00052 GHR ligand; PRLR ligand Hormone replacement drug Under clinical trials Details
D530 GDD3898 Chemical drug -- -- Hepatoprotectants; Obesity therapies Under clinical trials Details
D538 Mazindol Chemical drug DB00579 -- -- Under clinical trials Details